UPDATE: Bank of America Downgrades MannKind Following Physician Survey

By: Benzinga
In a report published Friday, Bank of America analyst Steve Byrne downgraded the rating on MannKind Corporation (NASDAQ: MNKD ) from Neutral to Underperform, and lowered the price target from $8.00 to $5.00. In the report, Bank of America noted, “We lowered our rating to Underperform and our PO to
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.